CTOs on the Move

ATAI Life Sciences

www.atai.life

 
Bridging the gap between what the #mentalhealth system can provide and what people need. Interested in #psychedelics, #drugdevelopment, and #AI. CEO @FloBrand.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.atai.life
  • 677, Huntington Avenue
    Boston, MA USA 02115
  • Phone: +49.89.2153903

Executives

Name Title Contact Details

Similar Companies

Noxilizer

Noxilizer, Inc. provides room-temperature nitrogen dioxide sterilization technology that offers many benefits over traditional sterilization methods. Noxilizer sells sterilization equipment to pharmaceutical, biotech and medical device manufacturers and also offers contract sterilization services at its Baltimore, MD facilities. Noxilizer’s expert microbiology and material compatibility team is ready to partner to solve sterilization challenges through every phase of the process. Noxilizer, Inc., founded in 2004, is privately held with offices in the US, United Kingdom, and Japan.

Biosearch Technologies

Biosearch Technologies is a Novato, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Genocea

Genocea is harnessing the power of T cell immunity to develop life-changing vaccines and immunotherapies. While traditional immunotherapy discovery methods have largely used predictive methods to propose T cell targets, or antigens, Genocea has successfully developed ATLAS™, its proprietary technology platform, to identify clinically relevant antigens of T cells based on actual human immune responses. Genocea is currently using ATLAS in immuno-oncology applications to develop neoantigen cancer vaccines, general cancer vaccines and a vaccine targeting cancers caused by Epstein-Barr Virus.

Terumo Interventional Systems

Terumo Interventional Systems is a Somerset, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Arno Therapeutics, Inc.

Arno Therapeutics is a clinical stage biopharmaceutical company developing innovative products for the treatment of cancer. Arno has exclusive worldwide rights to develop and market three innovative anti-cancer product candidates. These compounds are in clinical or preclinical development as product candidates to treat hematologic malignancies and solid tumors.